Haematology 2018

Conclusions (1)

• Anti -PD-1-pathway-blocking agents highly active in HL but more limited efficacy in other lymphomas. Mechanistic insights are emerging in HL

• Currently very large number of combination therapies involving anti-PD- 1/PD-L1 agents and conventional chemotherapies, targeted therapies, or other immunotherapies are being studied

• CAR-T cells look promising in relapsed and refractory DLBCL and other lymphoid malignancies. Efficacy and validity of delivery require on-going further international studies

• Clinical trials outrunning new immunological scientific insights.